Zoetis

ZTS · NYSE

$80.04+$0.45 (+0.57%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $79.59

ZTS analyst rating

HoldConsensus of 17 analysts over the last 12 months. 41% rate it a buy.

Strong buy0
Buy7
Hold10
Underperform0
Sell0

12-month price target · 17 analysts

Average $101.29 (+26.5% upside)

Low: $80.80
Now: $80.04
High: $168.00

Upgrades and downgrades

The latest rating actions, newest first

ZTS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Oct 20, 2026	Downgrade	Buy → Hold	$103.00 → $83.00	50%
Goldman Sachs	Oct 16, 2026	Initiates	Neutral	$74.00	80%
TD Cowen	Aug 25, 2026	Maintains	Buy	$104.00 → $94.00	76%
Stifel	Aug 20, 2026	Maintains	Hold	$85.00 → $80.00	55%
Citigroup	Aug 11, 2026	Maintains	Buy	$112.00 → $96.00	44%
BNP Paribas	Aug 11, 2026	Maintains	Outperform	$146.00 → $110.00	63%
Piper Sandler	Aug 10, 2026	Maintains	Neutral	$90.00 → $80.00	58%
UBS	Aug 7, 2026	Maintains	Neutral	$85.00 → $80.00	83%
JP Morgan	Aug 7, 2026	Maintains	Overweight	$130.00 → $115.00	65%
William Blair	Aug 6, 2026	Downgrade	Outperform → Market Perform	—	67%

The case for and against

Updated May 5, 2026

Bull case

Zoetis is poised for growth in the animal health market with a strong pipeline and a loyal customer base, despite facing competition and external challenges. Their focus on new product launches and investments in the companion animal market make them a leader in the industry, although they may encounter some headwinds from larger competitors and potential economic and political risks. Overall, ZTS's strong market share and promising R&D plans make it a favorable investment option for the long-term.

Bear case

Zoetis is a global leader in the animal health industry and has a solid market position with a strong customer base, but potential negative factors include the risk of outbreaks of infectious disease carried by animals, reliance on third parties for products and materials, and a premium valuation on the stock. There is also potential for competition in the pet dermatology market and recent challenges in the animal health end-market such as staffing shortages and inflationary pressures. However, potential opportunities for the company include the growing human-animal bond and an expanding global population driving demand for animal protein.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.